These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12463316)

  • 21. [The study of soluble P-selectin levels and it's correlation to the severity of coronary artery lesions in coronary heart disease].
    Qu XB; Sun ZQ; Chen MJ; Chen LL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Aug; 26(8):617-21. PubMed ID: 16390014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expression and significance of serum caveolin-1 in patients with Kawasaki disease.
    Zhu F; Huang J; Wang X; Li P; Yan Y; Zheng Y; He Y; Wu T; Ren Y; Wu R
    Chin J Physiol; 2020; 63(2):90-94. PubMed ID: 32341235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical relevance of the risk factors for coronary artery lesions in Kawasaki disease.
    Weng KP; Hsieh KS; Huang SH; Ou SF; Ma CY; Ho TY; Lai CR; Ger LP
    Kaohsiung J Med Sci; 2012 Jan; 28(1):23-9. PubMed ID: 22226058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice].
    Zhang QY; Du JB; Chen YH; Li WZ
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):886-90. PubMed ID: 17254452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of serum soluble TNF receptor II level and soluble TNF receptor II/I ratio as indicators of coronary artery lesion development in Kawasaki disease.
    Shimizu M; Mizuta M; Usami M; Inoue N; Sakakibara Y; Yamada K; Konishi M; Ohta K; Yachie A
    Cytokine; 2018 Aug; 108():168-172. PubMed ID: 29625336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum Levels of Syndecan-1 in Patients With Kawasaki Disease.
    Luo L; Feng S; Wu Y; Su Y; Jing F; Yi Q
    Pediatr Infect Dis J; 2019 Jan; 38(1):89-94. PubMed ID: 29601451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distribution of distinct subsets of circulating T follicular helper cells in Kawasaki disease.
    Xu M; Jiang Y; Wang J; Liu D; Wang S; Yi H; Yang S
    BMC Pediatr; 2019 Jan; 19(1):43. PubMed ID: 30704426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-10 polymorphisms are associated with coronary artery lesions in acute stage of Kawasaki disease.
    Weng KP; Hsieh KS; Hwang YT; Huang SH; Lai TJ; Yuh YS; Hou YY; Lin CC; Huang SC; Chang CK; Lin MW; Ger LP
    Circ J; 2010 May; 74(5):983-9. PubMed ID: 20339193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease.
    Honkanen VE; McCrindle BW; Laxer RM; Feldman BM; Schneider R; Silverman ED
    Pediatr Cardiol; 2003; 24(2):122-6. PubMed ID: 12457252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating soluble L-selectin levels in Kawasaki disease with coronary artery lesions.
    Hirao J; Yamashita T
    Acta Paediatr Jpn; 1997 Apr; 39(2):290-2. PubMed ID: 9141275
    [No Abstract]   [Full Text] [Related]  

  • 31. Association between adropin and coronary artery lesions in children with Kawasaki disease.
    Yang M; Pei Q; Zhang J; Weng H; Jing F; Yi Q
    Eur J Pediatr; 2021 Jul; 180(7):2253-2259. PubMed ID: 33712900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble LR11 is a novel biomarker for vascular lesions late after Kawasaki disease.
    Watanabe K; Suzuki H; Jiang M; Haniu H; Numano F; Hoshina S; Saitoh A; Uchiyama M; Bujo H
    Atherosclerosis; 2016 Mar; 246():94-7. PubMed ID: 26761773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corticosteroid Therapy Might be Associated with the Development of Coronary Aneurysm in Children with Kawasaki Disease.
    Zhao CN; Du ZD; Gao LL
    Chin Med J (Engl); 2016 Apr; 129(8):922-8. PubMed ID: 27064036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Red Blood Cell Distribution Width as a Predictive Marker for Coronary Artery Lesions in Patients with Kawasaki Disease.
    Ming L; Cao HL; Li Q; Yu G
    Pediatr Cardiol; 2021 Oct; 42(7):1496-1503. PubMed ID: 34036412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pro-brain natriuretic peptide (ProBNP) levels in North Indian children with Kawasaki disease.
    Reddy M; Singh S; Rawat A; Sharma A; Suri D; Rohit MK
    Rheumatol Int; 2016 Apr; 36(4):551-9. PubMed ID: 26849890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased levels of circulating fibroblast growth factor 21 in children with Kawasaki disease.
    Peng Y; Pei Q; Feng S; Su Y; Liu R; Yi Q; Guo P
    Clin Exp Med; 2019 Nov; 19(4):457-462. PubMed ID: 31478099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Procalcitonin (PCT) and Kawasaki Disease: Does PCT Correlate With IVIG-Resistant Disease, Admission to the Intensive Care Unit, or Development of Coronary Artery Lesions?
    Dominguez SR; Martin B; Heizer H; Jone PN; Tong S; Davidson J; Anderson MS; Glodé MP
    J Pediatric Infect Dis Soc; 2016 Sep; 5(3):297-302. PubMed ID: 26407256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prediction of the risk of coronary arterial lesions in Kawasaki disease by N-terminal pro-brain natriuretic peptide].
    Huiling L; Yaping L; Xiufen H
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):300-3. PubMed ID: 26182507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reappraisal of VEGF in the Pathogenesis of Kawasaki Disease.
    Chen CY; Huang SH; Chien KJ; Lai TJ; Chang WH; Hsieh KS; Weng KP
    Children (Basel); 2022 Sep; 9(9):. PubMed ID: 36138652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of fecal calprotectin and initial coronary dimensions to predict coronary artery lesions persistence in Kawasaki disease.
    Fabi M; Filice E; Andreozzi L; Mattesini BE; Rizzello A; Palleri D; Dajti E; Zagari RM; Lanari M
    Sci Rep; 2022 May; 12(1):8640. PubMed ID: 35606405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.